A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in men

  • Anne S. Reiner
  • Lindsay M. Jacks
  • Kimberly J. Van Zee
  • Katherine S. Panageas
Brief Report

Abstract

Each year there are an estimated 200,000 new breast cancer cases diagnosed in the United States; of these, 1% of cases are in men. Lymphedema can be a devastating complication from breast cancer and its treatment. Currently, almost all lymphedema-related research is based on women and extrapolated to men. We conducted the first population-based study of men with incident breast cancer of any stage, diagnosed from 1998 to 2005, who were 65 years and older in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. We utilized claims related to lymphedema and lymphedema treatment in our cohort. We defined ‘lymphedema-specific’ claims to contain the word ‘lymphedema’ in the Medicare claim description; similarly, ‘lymphedema-related’ claims were defined as treatments reimbursed for lymphedema but not necessarily containing the word ‘lymphedema’ in the Medicare claim description. We identified 628 men with incident breast cancer from 1998 to 2005 who were 65 years and older. The cumulative incidence, censored for deaths, of lymphedema-specific claims at 2, 3, 4, and 5 years was 8.0, 9.2, 10.5, and 10.5%, respectively. The median follow-up was 3.4 years and for those without any event was 4.7 years. The cumulative incidence, censored for deaths, of lymphedema-related claims at 2, 3, 4, and 5 years was 26.9, 32.2, 35.4, and 39.8%. Rates for men were similar to analogous rates for women. Lymphedema is a common complication affecting men with breast cancer as well as women and appropriate treatment and rehabilitation strategies need to be implemented for both genders.

Keywords

Breast cancer Population-based Male Lymphedema SEER Men 

Abbreviations

SEER

Surveillance, Epidemiology, and End Results

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:277–300PubMedCrossRefGoogle Scholar
  2. 2.
    Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL (2001) Arm edema in breast cancer patients. J Natl Cancer Inst 93(2):96–111PubMedCrossRefGoogle Scholar
  3. 3.
    McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockaway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol 26(32):5220–5226PubMedCrossRefGoogle Scholar
  4. 4.
    Petrek JA, Heelan MC (1998) Incidence of breast carcinoma-related lymphedema. Cancer 83(12 Suppl American):2776–2781PubMedCrossRefGoogle Scholar
  5. 5.
    Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Angela DeMichele, Solin LJ (2009) Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 27(3):390–397PubMedCrossRefGoogle Scholar
  6. 6.
    Armer J, Fu MR (2005) Age differences in post-breast cancer lymphedema signs and symptoms. Cancer Nurs 28(3):200–207PubMedCrossRefGoogle Scholar
  7. 7.
    Yen TWF, Fan X, Sparapani R, Purushuttom WL, Walker AP, Nattinger AB (2009) A contemporary, population-based study of lymphedema risk factors in older women with breast cancer. Ann Surg Oncol 16(4):979–988PubMedCrossRefGoogle Scholar
  8. 8.
    Clough-Gorr KM, Ganz PA, Silliman RA (2010) Older breast cancer survivors: factors associated with self-reported symptoms of persistent lymphedema over 20 years. Breast J 16(2):147–155PubMedCrossRefGoogle Scholar
  9. 9.
    Meek AG (1998) Breast radiotherapy and lymphedema. Cancer 83(S12B):2788–2797PubMedCrossRefGoogle Scholar
  10. 10.
    Petrek JA, Lerner R (1996) Lymphedema. In: Harris JR, Lippman ME et al (eds) Diseases of the breast. Lippincott-Raven, Philadelphia, pp 896–900Google Scholar
  11. 11.
    Gerber LH (2008) A review of measures of lymphedema. Cancer 83(12 Suppl):2803–2804Google Scholar
  12. 12.
    Armer JM, Radina ME, Porock D, Culbertson SD (2003) Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 52(6):370–379PubMedCrossRefGoogle Scholar
  13. 13.
    Launois R, Alliot F (2000) Quality of life scale in upper limb lymphoedema—a validation study. Lymphology 33:266–274Google Scholar
  14. 14.
    Launois R, Megnigbeto AC, Pocquet K, Alliot F (2001) A specific quality of life scale in upper limb lymphedema: the ULL-27 questionnaire. In: Campisi C, Witte MH, Witte CL (eds) Progress in lymphology XVIII international congress of lymphology, Sept 2001, Genoa. Lymphology 35(suppl):1–760, 2002:181–187Google Scholar
  15. 15.
    National Cancer Institute (2008) Lymphedema (PDQ). http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/HealthProfessional. Accessed 9 Sept 2008
  16. 16.
    American Cancer Society (2008) Understanding lymphedema. http://www.cancer.org/docroot/MIT/content/MIT_7_2x_Understanding_Lymphedema.asp. Accessed 21 Mar 2008
  17. 17.
    Mallon EC, Ryan TJ (1994) Lymphedema and wound healing. Clin Dermatol 12(1):89–93PubMedCrossRefGoogle Scholar
  18. 18.
    Aetna (2010) Clinical policy bulletin: lymphedema treatments. http://www.aetna.com/cpb/medical/data/1_99/0069.html. Accessed 28 May 2010
  19. 19.
    Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT (2002) Variations in morbidity after radical prostatectomy. N Engl J Med 346(15):1138–1144PubMedCrossRefGoogle Scholar
  20. 20.
    Bekelman JE, Mitra N, Efstathiou J, Liao K, Sunderland R, Yeboa DN, Armstrong K (2011) Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2011.02.006
  21. 21.
    Smith GL, Smith BD, Giordano SH, Shih YC, Woodward WA, Strom EA, Perkins GH, Tereffe W, Yu TK, Buchholz TA (2008) Risk of hypothyroidism in older breast cancer patients treated with radiation. Cancer 112(6):1371–1379PubMedCrossRefGoogle Scholar
  22. 22.
    National Cancer Institute (2011) Surveillance, Epidemiology, and End Results (SEER) Program. www.seer.cancer.gov. Accessed 6 June 2011
  23. 23.
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3-18Google Scholar
  24. 24.
    Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Anne S. Reiner
    • 1
  • Lindsay M. Jacks
    • 2
  • Kimberly J. Van Zee
    • 3
  • Katherine S. Panageas
    • 1
  1. 1.Department of Epidemiology and BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Cancer Care OntarioTorontoUSA
  3. 3.Department of SurgeryMemorial Sloan-Kettering Cancer Center, Evelyn H. Lauder Breast CenterNew YorkUSA

Personalised recommendations